| Identification | Back Directory | [Name]
Lazertinib | [CAS]
1903008-80-9 | [Synonyms]
CS-2767
GNS1480
YH25448
GNS-1480
Lazertinib
Lazertinib (YH25448)
Lazertinib(YH25448,GNS-1480)
YH 25448;YH25448;GNS-1480;GNS1480
LAZERTINIB; YH-25448; YH 25448; YH25448; GNS-1480; GNS 1480; GNS1480.
2-Propenamide, N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]-4-methoxy-2-(4-morpholinyl)phenyl]- | [Molecular Formula]
C30H34N8O3 | [MDL Number]
MFCD31728331 | [MOL File]
1903008-80-9.mol | [Molecular Weight]
554.64 |
| Chemical Properties | Back Directory | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:6.5(Max Conc. mg/mL);11.72(Max Conc. mM) | [form ]
A solid | [pka]
12.39±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Lazertinib is used in the preparation of heteroaryl pyrimidinylamine compounds for modulating EGFR mutant kinase activities. EGFR tyrosine-kinase inhibitor. |
|
|